Active, not recruitingPhase 2NCT06307431
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Studying MITF-related melanoma and renal cell carcinoma predisposition syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Intismeran autogene(biological)
- Enrollment
- 272 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2032
Study locations (30)
- City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104), Duarte, California, United States
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro, Los Angeles, California, United States
- UCSF Medical Center at Mission Bay ( Site 0108), San Francisco, California, United States
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0102), New Haven, Connecticut, United States
- Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 0109), Boston, Massachusetts, United States
- Dana-Farber Cancer Institute-GU ( Site 0101), Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center ( Site 0100), New York, New York, United States
- Duke Cancer Institute ( Site 0106), Durham, North Carolina, United States
- Abramson Cancer Center ( Site 0107), Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center ( Site 0111), Philadelphia, Pennsylvania, United States
- UT Southwestern Medical Center ( Site 0110), Dallas, Texas, United States
- Hospital Británico de Buenos Aires-Oncology ( Site 1106), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
- Instituto Alexander Fleming-Alexander Fleming ( Site 1101), Buenos Aires, Buenos Aires F.D., Argentina
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 1110), Buenos Aires, Buenos Aires F.D., Argentina
- Centro Privado de RMI Rio Cuarto ( Site 1104), Río Cuarto, Córdoba Province, Argentina
- +15 more locations on ClinicalTrials.gov
Collaborators
ModernaTX, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06307431 on ClinicalTrials.govOther trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05078047Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOUNICANCER
- ACTIVE NOT RECRUITINGPHASE1NCT04707248A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian TumorsDaiichi Sankyo
- RECRUITINGNCT05785052Biomarkers of Renal CancerBiorek S.R.L.
- ACTIVE NOT RECRUITINGPHASE1NCT03170960Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsExelixis
- RECRUITINGNCT00001238Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersNational Cancer Institute (NCI)
See all trials for MITF-related melanoma and renal cell carcinoma predisposition syndrome →